Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:COVCVE:LTYNASDAQ:ONCNASDAQ:PDP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOV(COV)$0.00$65.97▼$108.57N/AN/A3.88 million shsN/ALTYLiberty BiopharmaC$2.00+∞C$2.00C$0.06▼C$2.74C$21.54MN/A23,286 shs700 shsONCBeOne Medicines$245.49+0.5%$247.70$142.00▼$287.88$26.91B0.28360,050 shs172,489 shsPDPInvesco Dorsey Wright Momentum ETF$109.09+1.4%$104.92$86.41▼$117.67$1.29B1.0222,242 shs34,894 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOV(COV)0.00%0.00%0.00%0.00%0.00%LTYLiberty Biopharma0.00%0.00%0.00%0.00%0.00%ONCBeOne Medicines0.00%+1.78%-4.95%+2.93%+24,548,999,900.00%PDPInvesco Dorsey Wright Momentum ETF0.00%+1.27%+2.68%+20.29%+10.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOV(COV)N/AN/AN/AN/AN/AN/AN/AN/ALTYLiberty BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AONCBeOne Medicines3.424 of 5 stars4.50.00.00.02.61.70.6PDPInvesco Dorsey Wright Momentum ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOV(COV) 0.00N/AN/AN/ALTYLiberty Biopharma 0.00N/AN/AN/AONCBeOne Medicines 3.00Buy$320.6730.62% UpsidePDPInvesco Dorsey Wright Momentum ETF 2.68Moderate Buy$109.09N/ACurrent Analyst Ratings BreakdownLatest LTY, ONC, COV, and PDP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025ONCBeOne MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$313.00 ➝ $330.006/27/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$317.00 ➝ $321.006/27/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$311.005/8/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.005/8/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$348.00 ➝ $350.004/28/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$312.00 ➝ $312.004/24/2025ONCBeOne MedicinesTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$334.00 ➝ $334.004/21/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$311.00 ➝ $317.004/16/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/10/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$348.00 ➝ $348.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOV(COV)N/AN/AN/AN/AN/AN/ALTYLiberty BiopharmaN/AN/AC$0.00 per share2,000.00C$0.79 per shareN/AONCBeOne Medicines$3.81B7.06N/AN/A$34.10 per share7.20PDPInvesco Dorsey Wright Momentum ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOV(COV)N/AN/A0.00N/AN/AN/AN/AN/AN/ALTYLiberty BiopharmaN/A-C$0.16N/A∞N/AN/AN/AN/AN/AONCBeOne Medicines-$644.79M-$3.72N/A345.76N/A-9.40%-7.55%-4.42%N/APDPInvesco Dorsey Wright Momentum ETFN/AN/A27.88∞N/AN/AN/AN/AN/ALatest LTY, ONC, COV, and PDP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ONCBeOne Medicines-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOV(COV)N/AN/AN/AN/AN/ALTYLiberty BiopharmaN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/APDPInvesco Dorsey Wright Momentum ETF$0.220.20%N/AN/AN/ALatest LTY, ONC, COV, and PDP DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/23/2025PDPInvesco Dorsey Wright Momentum ETFQuarterly$0.04290.16%6/23/20256/23/20256/27/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOV(COV)N/AN/AN/ALTYLiberty Biopharma8.190.120.12ONCBeOne Medicines0.051.961.71PDPInvesco Dorsey Wright Momentum ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOV(COV)N/ALTYLiberty BiopharmaN/AONCBeOne Medicines48.55%PDPInvesco Dorsey Wright Momentum ETFN/AInsider OwnershipCompanyInsider OwnershipCOV(COV)N/ALTYLiberty BiopharmaN/AONCBeOne Medicines6.62%PDPInvesco Dorsey Wright Momentum ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOV(COV)N/AN/AN/ANot OptionableLTYLiberty BiopharmaN/A10.77 millionN/ANot OptionableONCBeOne Medicines11,000109.60 million102.34 millionN/APDPInvesco Dorsey Wright Momentum ETFN/A11.85 millionN/AOptionableLTY, ONC, COV, and PDP HeadlinesRecent News About These CompaniesHigh-Beta & Momentum ETFs to Play on Hints of Easing Trade Tensions?April 23, 2025 | zacks.comETFs For The Brave: Are These High-Octane Funds Your Best Bet To Ride An Upward Market Swing?April 15, 2025 | benzinga.comBuy High Beta & High Momentum ETFs for Near-Term GainsApril 10, 2025 | zacks.comBuy High Beta & High Momentum ETFs for Near-Term GainsApril 10, 2025 | zacks.comInvesco Exchange-Traded Fund Trust Invesco Dorsey Wright Momentum ETFMarch 25, 2025 | fxempire.comFPIZ Invesco Dorsey Wright Developed Markets Momentum ETFNovember 22, 2024 | seekingalpha.comPDP, TRGP, WRB, TDG: Large Inflows Detected at ETFOctober 3, 2024 | nasdaq.com(PDP) Investment AnalysisSeptember 17, 2024 | news.stocktradersdaily.comNPDP Invesco Dorsey Wright Momentum ETFAugust 28, 2024 | seekingalpha.comTime for Momentum ETFs?August 20, 2024 | zacks.comMomentum ETFs to Play as Wall Street Rallies?August 16, 2024 | zacks.comInvesco Dorsey Wright Momentum ETF (PDP)November 28, 2023 | finance.yahoo.comInvesco DWA Developed Markets Momentum ETF (PIZ)August 18, 2023 | investing.comInvesco DWA Emerging Markets Momentum ETFJune 30, 2023 | thestreet.comIs Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) a Strong ETF Right Now?February 24, 2023 | msn.comGTO Invesco Actively Managed Exchange-Traded Fund Trust - Invesco Total Return Bond ETFFebruary 23, 2023 | seekingalpha.comInvesco DWA Consumer Cyclicals Momentum ETF (PEZ)December 25, 2022 | finance.yahoo.comPEZ Invesco Exchange-Traded Fund Trust - Invesco DWA Consumer Cyclicals Momentum ETFOctober 11, 2022 | seekingalpha.comInvesco DWA Momentum ETF declares quarterly distribution of $0.0830September 21, 2022 | seekingalpha.comInvesco DWA Momentum ETF declares quarterly distribution of $0.0237June 21, 2022 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesRKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?3 Summer Short-Squeeze Candidates With Catalysts for CoveringBy Thomas Hughes | June 30, 2025View 3 Summer Short-Squeeze Candidates With Catalysts for CoveringIntel's Price Spikes: Noise, or the First Notes of a Turnaround?By Jeffrey Neal Johnson | June 13, 2025View Intel's Price Spikes: Noise, or the First Notes of a Turnaround?Want AI Exposure? These 3 ETFs Offer Different AnglesBy Chris Markoch | June 9, 2025View Want AI Exposure? These 3 ETFs Offer Different AnglesWhy Realty Income’s 5.59% Yield Makes It a Must-Buy REITBy Jeffrey Neal Johnson | July 2, 2025View Why Realty Income’s 5.59% Yield Makes It a Must-Buy REITLTY, ONC, COV, and PDP Company Descriptions(COV) NYSE:COVCovidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company's brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company's segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company's products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.Liberty Biopharma CVE:LTYC$2.00 +2.00 (+∞) As of 10/10/2018Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada.BeOne Medicines NASDAQ:ONC$245.49 +1.17 (+0.48%) As of 07/3/2025 01:00 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Invesco Dorsey Wright Momentum ETF NASDAQ:PDP$109.09 +1.54 (+1.43%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PowerShares DWA Technical Leaders Portfolio (the Fund) is based on the Dorsey Wright Technical Leaders Index (the Index). The Fund seeks investment results that generally correspond to the price and yield of the Index. The Fund will normally invest at least 90% of its total assets in securities that consists of the Index and American Depositary Receipts (ADRs) based on the securities in the Index. The Index includes approximately 100 the United States-listed companies. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
